2/10
08:05 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
1/6
10:42 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
1/6
10:42 am
zbio
Rating for ZBIO
Medium
Report
Rating for ZBIO
1/5
04:00 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
1/5
04:00 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
12/22
08:42 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
12/22
08:42 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
12/22
08:38 am
zbio
Rating for ZBIO
High
Report
Rating for ZBIO
12/22
08:38 am
zbio
Rating for ZBIO
High
Report
Rating for ZBIO
12/16
08:43 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.